PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon

Learn more about the emerging evidence of PROTAC ER degraders to treat estrogen receptor–positive/HER2-negative metastatic breast cancer, including mechanisms of action and how these novel therapies compare to standard-of-care endocrine therapies. 

Share

Program Content

Activities

PROTACs in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: April 18, 2025

PROTACs: Data in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future
Video
Congratulations: You achieved a completion on 04/09/2022

Released: November 14, 2024

Expires: April 13, 2025

Activities

PROTACs in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: November 18, 2025

PROTACs: Data in ER+/HER2- MBC
PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future 
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2024

Expires: November 18, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.